title: [Biological therapies in systemic lupus erythematosus].
abstract: The prevention of chronic organic damage and complete inhibition of inflammatory activity of the disease are the main goals in the treatment of systemic lupus erythematosus (SLE). Current therapies of SLE are not effective enough and they may cause various serious side effects. Biological therapies, affecting important pathogenetic disturbances in the immunological system of SLE patients, give hope for the development of a new treatment for SLE. Currently the most advanced clinical trials are being conducted with anti-lymphocyte B drugs, such as rituximab, belimumab and epratuzumab. Belimumab as the first biological agent was registered for treatment of the active, seropositive form of SLE. The advances in immunology and rheumatology nowadays raise the hope of finding effective and safe treatment for SLE. In our article we present an overview of data concerning perspectives of biological treatment in SLE.
authors.affiliation: Katedra i Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Uniwersytet Medyczny, Lublin. suszekdorota@wp.pl
authors.forename: Dorota
authors.initials: D
authors.lastname: Suszek
authors.forename: Radosław
authors.initials: R
authors.lastname: Jeleniewicz
authors.forename: Maria
authors.initials: M
authors.lastname: Majdan
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors*; D001691:Biological Therapy; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D053264:B-Cell Activating Factor; D011993:Recombinant Fusion Proteins; C505719:TNFSF13B protein, human; C448700:epratuzumab; D000069283:Rituximab; C511911:belimumab; C524618:TACI receptor-IgG Fc fragment fusion protein